UK-based pharmaceutical company KalVista has dosed the first patient in its Phase I first-in-human clinical trial of KVD818 to treat hereditary angioedema (HAE).

KalVista-developed KVD818 is a new potent product that selectively inhibits plasma kallikrein, thereby preventing attacks of edema in patients suffering from HAE.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Plasma kallikrein is a serine protease and a key component of the body’s inflammatory response, which is responsible for the dilation of blood vessels and increased vascular permeability, edema, and inflammation.

Conducted in the UK, the clinical trial has been designed to assess the safety, drug exposure and bioactivity (plasma kallikrein inhibition) of KVD818 following its oral administration to patients.

"We believe that an oral drug for the treatment of HAE will be an important advancement for patients who suffer from this condition."

The result of the trial is expected to be announced early next year.

KalVista CEO Andrew Crockett said: “The successful dosing of the first subject in this first-in-human clinical trial is an important milestone for the KVD818 development programme and a first step in our goal of developing a best in class oral plasma kallikrein inhibitor for HAE.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We believe that an oral drug for the treatment of HAE will be an important advancement for patients who suffer from this condition.”

HAE is a rarely occurring, malignant genetic condition triggering symptoms such as sudden and prolonged attacks of edema, which often occur in the hands, feet, face, gastrointestinal tract, and airway.

The attacks can result in severe swelling and pain, airway blockage, and nausea. The treatment of HAE includes addressing both prophylaxis and management of acute attacks.

KalVista is planning to conduct the Phase II trial of KVD818 for HAE depending on the Phase I study results.